All In Biotech

Drug Trial Radar · NCT04445363

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata

A Phase I/II Study Of The Efficacy,Safety and Pharmacokinetics Of Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

160

Actual

Start

Aug 12, 2020

Primary completion

Dec 1, 2024

Study completion Dec 1, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study includes a dose escalation part(phase I) and a dose extension part(phase II).

Conditions

  • Alopecia Areata(AA)

Interventions

  • Jaktinib hydrochloride creamDrug

    Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

  • PlaceboDrug

    Dose extension: Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving 90% Improvement of Severity of Alopecia Tool (SALT90)Time frame: at week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Xaingya Hospital,central south university

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.